Italy moves to integrate public and private in health
This article was originally published in Clinica
Executive Summary
Italian health minister Girolamo Sirchia last week announced a reshuffle of responsibilities within the ministry, with a direct bearing on the functions that affect the medical technology industry. The move, which also redefines the management of the national healthcare institute (ISS) and of the national institute for preventive health and health and safety at work (ISPESL), is in response to the passage of Law 145 of July 15 2002, which sets out measures to "promote the exchange of experiences and greater interaction between the public and private sectors". The law came into effect on October 8 2002.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.